TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00793000
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo to match 1000 mg oral dose (prepared solution), given once
Study: NCT04411082
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration of once daily Placebo
Study: NCT02401529
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25mg/kg/day for 7 days then tapering for next 7 days
Study: NCT02401529
Drug: IV saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV saline
Study: NCT01755286
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intratympanic injection
Study: NCT01755286
Drug: Sham
Normalized name: SHAMPOO
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simulated single intratympanic injection
Study: NCT02182882
Drug: GINSANA
Normalized name: Ginsana 200mg Softgel
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02182882
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00793000
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo to match 1250 mg oral dose (prepared solution), given once
Study: NCT00793000
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo to match 1500 mg oral dose (prepared solution), given once
Study: NCT01691989
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral doses once a day for 26 weeks
Study: NCT01470313
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is normal saline. The timing of placebo administration will depend of the dosing frequency of the cohort (either every other week for 3 months or every 4 weeks for 3 months).
Study: NCT04056169
Drug: high-dose rosuvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosuvastatin 20 mg once a day for 6 months
Study: NCT04056169
Drug: low-dose rosuvastatin plus ezetimibe
Normalized name: ezetimibe / rosuvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: ezetimibe/rosuvastatin 10/5 mg once a day for 6 months
Study: NCT02037893
Drug: Antipyrine Otic Solution
Normalized name: antipyrine Otic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipyrine 54 mg and glycerine dehydrated to 1.0 mL
Study: NCT02037893
Drug: Benzocaine Otic Solution
Normalized name: Benzocaine Otic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: benzocaine 14 mg and glycerine dehydrated to 1.0 mL
Study: NCT02037893
Drug: Placebo Otic solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo otic solution will be glycerin that is dehydrated
Study: NCT04454424
Drug: BAY1817080
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study intervention BAY1817080 will be administered orally with tablet(s).
Study: NCT01089556
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally, daily as a blind for duloxetine and/or pregabalin for 8 or 16 weeks
Study: NCT02783638
Drug: YHD1119
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 by 2
Study: NCT03040219
Drug: Folic Acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablets
Study: NCT02896192
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily SC injection
Study: NCT01097980
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00551213
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00551213
Drug: FOLFOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leucovorin calcium (folinic acid)(FOL) + 5-fluorouracil (F)+ oxaliplatin (OX)
Study: NCT00551213
Drug: FOLFIRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leucovorin calcium (folinic acid)(FOL) + 5-fluorouracil (F)+ irinotecan (IRI)
Study: NCT01922934
Drug: Obesity pharmacotherapy
Normalized name: DIET FORMULATIONS FOR TREATMENT OF OBESITY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phentermine or phentermine-topiramate (Qsymia)
Study: NCT01061372
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, orally administered once a day, 1-3 hours before bedtime for 12 weeks
Study: NCT00292812
Drug: Nutritional supplementation (nucleotides)
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03292302
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo comparator
Study: NCT01890967
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT01890967
Drug: Statin
Normalized name: Statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT02945306
Drug: Watchful waiting with supportive care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of widely prescribed medicines to treat associated conditions
Study: NCT01036087
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 500 mg/m2 IV every 3 weeks starting on Day 1 of Week 14 (4 cycles, each 3 weeks long, over 12 weeks).
Study: NCT03805360
Drug: Normal Saline Flush, 0.9% Injectable Solution
Normalized name: Normal Saline Flush, 0.9% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal Saline Flush, 0.9% Injectable Solution is not expected to provide numbness to the chest wall when injected into the erector spinae plane.
Study: NCT02343614
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00714337
Drug: AZD1386
Approvals — FDA: no, EMA: no, PMDA: no
Description: One single oral dose of 90mg (36mL of AZD1386 2.5mg/mL oral solution).
Study: NCT00855218
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 tablets of placebo will be taken daily (2 tablets b.i.d). TACE using DC Bead
Study: NCT00688441
Drug: Nasal CO2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily during the 14 day Treatment Period
Study: NCT00688441
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of the study drug dispenser at the same frequency as the active arm
Study: NCT04364945
Drug: remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: administration of remifentanil 0.1-0.2 mcg/kg/min
Study: NCT03971695
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule or Oral solution
Study: NCT03905811
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 capsule by mouth daily at bedtime
Study: NCT00714337
Drug: AZD1386
Approvals — FDA: no, EMA: no, PMDA: no
Description: One single oral dose of 90mg (3 x 30mg AZD1386 capsules)
Study: NCT00445900
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00790608
Drug: Nitric Oxide
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gaseous nitric oxide (1%), delivered for 30 minutes per day for 3 consecutive days
Study: NCT00837551
Drug: WBI-1001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doses of 0,0.5% and 1.0% cream. Topical cream application. Twice daily for 28 days. Duration of treatment: 28 days with one week follow-up.
Study: NCT04400266
Drug: Mealatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Melatonin 3mg once nightly
Study: NCT00044993
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02333851
Drug: Mixtard 30:70 Novonordisk® twice daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Premixed insulin twice daily before breakfast and before dinner
Study: NCT02333851
Drug: Lantus® once daily and Apidra® before meals
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of Lantus® insulin once daily and rapid insulin Apidra® before breakfast, lunch and dinner
Study: NCT00549497
Drug: GW870086X
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03415178
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pharmaceutical form:tablet Route of administration: oral
Study: NCT00523432
Drug: CCI-779 (temsirolimus)
Normalized name: dengue virus live antigen, CYD serotype 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly 25mg dose via IV infusion.
Study: NCT03607539
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL:100 mg，200mg，Q3W (qualer 3 weeks), day1, I.V.
Study: NCT01324115
Drug: NG-nitro-L-arginine
Normalized name: NG-nitro-L-arginine methyl ester
DrugBank: N-omega-nitro-L-arginine methyl ester (DB12750)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02991001
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02273167
Drug: NER1006, 2-Day Split-Dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: The subject will self-administer the first dose of the assigned investigational product in the evening prior to the scheduled colonoscopy and take mandatory additional clear fluid. Subject will take the second dose together with mandatory additional clear fluids on the morning of the colonoscopy.
Study: NCT02273167
Drug: NER1006,1-Day Morning Split-Dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: The subject will self-administer the first dose of the investigational product on the morning of the colonoscopy and take mandatory additional clear fluid.~After a 1-2 hour break the subject will self-administer the second dose plus additional clear mandatory fluid.
Study: NCT02273167
Drug: MOVIPREP, 2-Day Split-Dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: The subject will self-administer the first dose of the assigned investigational product in the evening prior to the scheduled colonoscopy and take recommended additional clear fluid. Subject will take the second dose together with recommended additional clear fluids on the morning of the colonoscopy.
Study: NCT01992042
Drug: Fluvastatin
Normalized name: Fluvastatin
DrugBank: Fluvastatin (DB01095)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HMG-CoA reductase inhibitors that lowers cholesterol levels. 40mg twice daily
Study: NCT00679237
Drug: betablocker, diuretics, ACEI, ARB,
Approvals — FDA: no, EMA: no, PMDA: no
Description: blood pressure control according to ESC guidelines
Study: NCT01769235
Drug: Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5% (Taro Pharmaceuticals Inc.)applied at approximately the same time once daily for 84 days (12 weeks).
Study: NCT02424344
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-matched placebo dry powder for oral inhalation twice daily via Genuair inhaler
Study: NCT03128203
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline, intranasally administrated
Study: NCT01769235
Drug: Acanya® Gel, 1.2%/2.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acanya® (Clindamycin Phosphate and Benzoyl Peroxide) Gel, 1.2%/2.5% (Dow Pharmaceutical Sciences, Inc., marketed by Valeant Pharmaceuticals North America LLC)applied at approximately the same time once daily for 84 days (12 weeks).
Study: NCT03311555
Drug: Androgen deprivation
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADT will consist of treatment with a GnRH agonist or antagonist per physician and institutional preference. Either leuprolide acetate (Lupron Depot, 22.5 mg or 45 mg IM), triptorelin pamoate (Trelstar, 11.25 mg or 22.5 mg IM), goserelin acetate (Zoladex, 10.8mg SC) or degarelix (Firmagon 120 mg or 240 mg SC) will be administered monthly, every 3 months, or every 6 months, depending on institutional standards, for 36 weeks total.
Study: NCT01445639
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: as placebo
Study: NCT02262143
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rosuvastatin 10 mg, qd, po
Study: NCT02146651
Drug: Humalog®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 0.2U/Kg body weight injected subcutaneously
Study: NCT00839228
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo one tablet bd for 3 months
Study: NCT01456663
Drug: AFQ056
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04533568
Drug: Ibuprofen 400 mg
Normalized name: ibuprofen 400 MG
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400mg intravenous ibuprofen with 10mg intravenous metoclopramide Hcl in 100ml 0.9% NaCl for 30 minutes.
Study: NCT02160626
Drug: A-101 (40) Topical Solution
Normalized name: OXT-101
Approvals — FDA: no, EMA: no, PMDA: no
Description: A-101 (40) Topical Solution - high dose
Study: NCT02160626
Drug: A-101 (32.5) Topical Solution
Normalized name: OXT-101
Approvals — FDA: no, EMA: no, PMDA: no
Description: A-101 (32.5) Topical Solution - low dose
Study: NCT04324229
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starting dose of placebo 0.1 ml will be administered for one week, after which dose will be escalated to placebo 0.2 ml for one week and thereafter placebo 0.3 ml s.c. daily injections.
Study: NCT01353235
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients assigned to corticotherapy arm, will receive oral prednisolone 1mg/kg/j as an add on therapy for a maximum of 10 days.
Study: NCT01746173
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01746173
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01689337
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matched to Sprifermin (AS902330) will be administered as intra-articular injection once every week for 3 weeks, starting from 2 weeks after MFx surgery.
Study: NCT02431013
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin 40 mg on Day 1 \& Day 8.
Study: NCT02431013
Drug: Pravastatin
Normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pravastatin 20 mg on Day 1 \& Day 8.
Study: NCT02657330
Drug: SBP-101
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous drug, escalating dose cohorts
Study: NCT01905696
Drug: Oral N-acetylcysteine
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01182025
Drug: Xiyanping Injection
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dosage for child medication:~5-10mg/kg/d (0.2-0.4ml/kg/d) in 5% Glucose solution, IV, with speed of 20-30 drops per minute, each day; or as directed by doctor.
Study: NCT03449459
Drug: aerosol inhaled amikacin
Normalized name: amikacin Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4g Amikacin sulfate injection + 5ml saline, aerosol inhalation, b.i.d., 5-7 days per month, for 3 months.~In order to observe and cope with adverse events timely, subjects will be admitted to the ward during the course of medication.~Subjects will take conventional therapy at the same time.
Study: NCT02040233
Drug: BAY1067197 (10 mg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg BAY1067197 for 7 d treatment once daily as oral application
Study: NCT02040233
Drug: BAY1067197
Approvals — FDA: no, EMA: no, PMDA: no
Description: The dose escalation to the second dose step will proceed only if the previous dose step has shown acceptable safety and tolerability 5 mg / or 10 mg / or 20 mg BAY1067197 for 7 d treatment as oral application.
Study: NCT02040233
Drug: Placebo (10 mg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg Placebo for 7 d treatment once daily as oral application
Study: NCT01703351
Drug: Fentanyl 500mcg + acupan 160mg + nasea 0.6mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: (n=48); IV PCA (Fentanyl 500mcg + acupan 160mg + nasea 0.6mg, 5cc/hr for 60 hours after operation, 0.5cc bolus if patients feel breakthrough pain)
Study: NCT03485625
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Two cannulae were placed, one in a vein on the dorsum of the operative hand and the other on the non operative hand for i.v fluids. The operative arm was elevated for 2 min and was then exsanguinated with an elastic bandage. A pneumatic tourniquet was then placed around the upper arm, and the cuff was inflated to 100 mm Hg above systolic BP. Circulatory isolation of the arm was verified by inspection, absence of a radial pulse, and a loss of the pulse oximetry tracing in the ipsilateral index fingers The solutions were prepared by an anesthesiology assistant not involved in any part of the study. The solutions were injected over 90 s by an anaesthesiologist.
Study: NCT02641054
Drug: CVXL-0107
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02641054
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02641054
Drug: Levodopa
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02953730
Drug: PEG-rhG-CSF
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02040233
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg / or 10 mg / or 20 mg Placebo for 7 d treatment once daily as oral application
Study: NCT02135952
Drug: MTZ+AMX
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration of antibiotics (metronidazole and amoxicillin) for 14 days started immediately after the first session of SRP.
Study: NCT01122251
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo of Lercanidipine and Valsartan
Study: NCT01607658
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo intranasal gel administered prn, 2-8 hours before a planned sexual event
Study: NCT01607658
Drug: Low dose TBS-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose testosterone intranasal gel administered prn 2-8 hrs before a planned sexual event
Study: NCT04459247
Drug: Vit D
Normalized name: Tri-Vit Drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral liquid formulation of 60000 IU
Study: NCT02344563
Drug: Mepem
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00343447
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01498679
Drug: GW685698/GW642444 (fluticasone furoate/vilanterol trifenatate)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICS/LABA combination (100/25mcg) administered once daily in the evening via a Novel Dry Powder Inhaler (NDPI)
Study: NCT01498679
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered once daily in the evening via a NDPI
Study: NCT04525300
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomization was performed with the use of a computer-generated system provided by the sponsor. Eligible patients were randomly assigned, in a 2:1 ratio, to receive once-daily subcutaneous injections of liraglutide, starting at a dose of 0.6 mg with weekly 0.6-mg increments to 3.0 mg, or placebo; both groups received counseling on lifestyle modification
Study: NCT03060473
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin 1 gm PO once
Study: NCT03060473
Drug: Erythromycin
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erythromycin 250 mg IV every 6 hours for 48 hours followed by 500 mg PO every 8 hours for 5 days.
Study: NCT00938899
Drug: TMC435350; Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01587833
Drug: Benzodiazepine (BZD) use, defined by ATC codes
Approvals — FDA: no, EMA: no, PMDA: no
Description: BZD prescription during the study period between January 1, 2001 and December 31, 2009
Study: NCT00477334
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral; two tablets twice a day; single day treatment
Study: NCT03528421
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Two days before cell infusion, all patients will be treated with Cyclophosphamide for 3 days
Study: NCT03176771
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: MT-5199 placebo capsules
Study: NCT02484677
Drug: 5-Fluorouracile
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antineoplastic and immunomodulating agents. Blood sampling for pharmacokinetic evaluation
Study: NCT00655291
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00039208
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04385420
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo film-coated tablet administered via oral route
Study: NCT00039208
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00641953
Drug: IMX-150
Approvals — FDA: no, EMA: no, PMDA: no
Description: (0.3%) 0.5g topically BID to each foot for 4 weeks
Study: NCT00641953
Drug: IMX-150
Approvals — FDA: no, EMA: no, PMDA: no
Description: (0.6%) 0.5g topically BID to each foot for 4 weeks
Study: NCT00641953
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 g topically BID to each foot for 4 weeks
Study: NCT03215810
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide will be administered at 60 mg/kg/day IV in 250 mL normal saline (NS) over approximately 2 hours. Cyclophosphamide will be initiated seven days prior to the anticipated TIL transfer, and the precise timing will depend on the rate of in vitro TIL growth. The dose will be based on the patient's body weight, but to prevent undue toxicity, it will not exceed a dose greater than 140% of the maximum ideal body weight per Metropolitan Life Insurance Company, Height and Weight Table.
Study: NCT00367237
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral methotrexate 15 mg/week for 15 weeks. Dose can be increased to 20 mg/week at Week 6.
Study: NCT00000577
Drug: Adrenal Cortex Hormones
Normalized name: adrenal cortex extract
Approvals — FDA: no, EMA: no, PMDA: no